Joe Lennerz, MD, PhD, Chief Scientific Officer at BostonGene, will discuss advancements in regulatory science within digital and computational pathology, emphasizing collaborative strategies to accelerate adoption in the U.S.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced its participation in Pathology Visions, taking place November 3-5, 2024, at the Hyatt Regency in Orlando, Florida. Pathology Visions brings together digital pathology experts and professionals to explore current and practical applications and future innovations shaping the field. This event offers a unique opportunity for immersive learning, featuring expert insights, groundbreaking research and exceptional networking opportunities.

During the event, Joe Lennerz, MD, PhD, Chief Scientific Officer at BostonGene, will moderate a panel session, “Advancing Regulatory Science in Digital and Computational Pathology: A Collaborative Dialogue.” This session, scheduled for Tuesday, November 5, will bring together industry, academia and regulatory bodies to drive advancements in regulatory science and accelerate digital pathology adoption in the U.S. It will showcase recent developments and offer diverse perspectives on these advancements.

“Pathology Visions offers a dynamic platform for driving progress in digital pathology. The conference brings together diverse experts from around the world," said Joe Lennerz, MD, PhD, Chief Scientific Officer at BostonGene. "I’m excited to moderate the discussion on advancing regulatory science. Collaborative efforts between industry, academia and regulatory bodies are essential to accelerate digital pathology adoption in the U.S. This conference is a valuable opportunity to share insights, explore innovative solutions and shape the future of pathology for better patient care.”

For more information, visit the Pathology Visions website.

About BostonGene Corporation

BostonGene is a biotechnology company specializing in advanced computational biology and precision medicine. Founded in 2015, BostonGene has consistently pushed the boundaries of innovation to improve patient care and accelerate drug development. Our AI-powered multiomics platform decodes cancer patients' molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets and recommend the most effective treatments. With advanced bioanalytics, an indication-specific cancer library and a next-generation CLIA-certified, CAP-accredited high-complexity laboratory, we deliver precise, clinically validated insights that drive precision medicine and advance oncology research. For more information, visit www.BostonGene.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241101181817/en/